Previous 10 | Next 10 |
Brian Stuglik to Retire from CEO Role; Continue to Serve on Company’s Board of Directors Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that Dan Paterson, P...
2023-07-07 20:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Randomized Phase 3 Trial (RAMP 301) Will Evaluate the Combination of Avutometinib and Defactinib vs Standard of Care Treatment; Study to Commence in 2H 2023 Recently Published Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability...
2023-06-16 08:13:05 ET Panbela Therapeutics ( PBLA ) -31% . Clene ( CLNN ) -28% prices $40M public offering. Applied UV ( AUVI ) -27% . EdtechX Holdings Acquisition II ( EDTX ) -13% . Creative Medical Technology Holdings ( CELZ ) -...
2023-06-16 05:45:41 ET Coherent: Discounted And Attractive Entry Point For The Medium To Long Term Lexicon Pharmaceuticals Secures Key FDA Approval, But Heavy Lifting Remains Federal Reserve Watch: Markets Are Saying That Other Central Banks Are 'Tighter' Than Th...
2023-06-16 05:30:22 ET Verastem Oncology, ( NASDAQ: VSTM ) has priced public offering of 7,181,409 shares of its common stock at of $9.75 per share and pre-funded warrants to purchase up to 1,538,591 shares of its common stock at $9.749 per pre-funded warrant. Shares down ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 7,181,409 shares of its common stock at a price to the public of $9.75 per share and, in lieu of common s...
2023-06-15 16:32:49 ET Verastem Oncology ( NASDAQ: VSTM ) plans to offer and sell common stock and pre-funded warrants in an underwritten public offering, the company said Thursday. The underwriters are expected to have a 30-day option to purchase up to an additional 15% of the ...
2023-06-15 10:06:53 ET Gainers: Aldeyra Therapeutics ( ALDX ) +11% . Bioventus ( BVS ) +11% . IO Biotech ( IOBT ) +11% . Verastem ( VSTM ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Losers: Mersana Therapeutics ( MRSN...
2023-06-15 09:39:31 ET Verastem, Inc. ( NASDAQ: VSTM ) added ~14% in the morning hours Thursday after Mizuho upgraded the clinical-stage biotech arguing that the recent data the company shared for its ovarian cancer therapy avutometinib could support its accelerated approval. ...
News, Short Squeeze, Breakout and More Instantly...
GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation dat...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that in connection with the 2024 Russell U.S. Indexes annual reconstitution, the company will be added to the Russell 3000 ® and Russell Microcap ...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...